Key result
The antero-posterior pituitary dimension was the most significant predictor for the necessity of using gadolinium-based contrast agents in children with growth or puberty disorders (OR 2.23).
Why the study?
Most pituitary MRI examinations in children with growth or puberty disorders might not require gadolinium-based contrast agent administration.
Does non-contrast MRI provide sufficient diagnostic accuracy compared to contrast-enhanced MRI for pituitary assessment in children with growth or puberty disorders?
Observational (n=567)
Single-blind
No
Does non-contrast MRI provide sufficient diagnostic accuracy compared to contrast-enhanced MRI for pituitary assessment in children with growth or puberty disorders?
In most children with growth or puberty disorders, non-contrast pituitary MRI is sufficient for diagnosis, and an antero-posterior dimension >7.5 mm can guide when contrast is necessary.
May support selective contrast use by pituitary dimensions in children; leaves open need for prospective validation before practice change.
Objectives Most of the pituitary MRI examinations in children with growth or puberty disorders (GPD) might not require gadolinium-based contrast agent (GBCA) administration. Methods Retrospective re-analysis of contrast-enhanced 567 pituitary MRIs of children with GPD. Two sets of sequences were created from each MRI examination: Set1 - common sequences without contrast administration and Set2 - common pre- and post-contrast sequences. The differences in the visibility of pituitary lesions between sets were statistically analyzed. Results The overall frequency of Rathke's cleft cysts was 11.6%, ectopic posterior pituitary 3.5% and microadenomas 0.9%. Lesions visible without contrast administration accounted for 85% of cases, while lesions diagnosed only after contrast injection accounted for 0.18% of all patients. Statistical analysis showed the advantage of antero-posterior (AP) pituitary dimension over other criteria in determining the appropriateness of using contrast in pituitary MRIs. The AP dimension was the most significant factor in logistic regression analysis: OR=2.23, 95%CI, 1.35-3.71, p-value=0.002 and in ROC analysis: AUC:72.9% with cut-off value 7.5 mm, with sensitivity/specificity rates: 69.2%/73.5%. Conclusions In most cases, the use of GBCA in pituitary MRI in children with GPD is unnecessary. The additional advantages of GBCA omission include: shortening the time of MRI examination and of general anesthesia.
No takes yet. Share an insight, caveat, or question.
Michali-Stolarska et al. (2021) conducted an observational in Growth or puberty disorders (n=567). Antero-posterior (AP) pituitary dimension was evaluated on Diagnostic incorrectness between non-contrast and contrast-enhanced MRI (OR 2.23, 95% CI 1.35-3.71, p=0.002). The antero-posterior pituitary dimension was the most significant predictor for the necessity of using gadolinium-based contrast agents in children with growth or puberty disorders (OR 2.23).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: